PTAB invalidates Sanofi injector patent
HJBC / Shutterstock.com
Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, Atomwise, artificial intelligence, AI, drug discovery, research and development, small-molecule drug candidates